Business News • PR NewsWire • eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

NIEL, Belgium, March 19, 2018 /PRNewswire/ -- ECI-006 is safe and well tolerated eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose...

View More : https://www.prnewswire.com/news-releases/etherna-completes-enrolment-of-low-dose-cohort-for-phase-1b-study-of-trimix-mrn...

Releted News by prnewswire

Emakina Group Results 2017: Continued International Growth and Positive Operating Margin Trend

Seattle Mayor Durkan, Amazon, Starbucks, Zillow and others convene to talk solutions to homelessness as part of United Way's Community Resource Exchange

La alcaldesa de Seattle Durkan, Amazon, Starbucks, Zillow y otros se reúnen para discutir soluciones a la falta de techo como parte de la Bolsa de Recursos Comunitarios de United Way

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma